월경곤란증 치료 : 시장 인사이트, 경쟁 구도, 시장 예측(-2032년)

Dysmenorrhea Treatment Market by Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), Treatment (Drugs, Devices, and Others), End-User (Hospitals, Gynecology & Wellness Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the high prevalence of dysmenorrhea (menstrual pain), increased awareness and diagnosis, and increasing product development and launches activities among the key players.

The dysmenorrhea treatment market was valued at USD 4,693.08 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 7,909.14 million by 2032. The high prevalence of dysmenorrhea (menstrual pain), coupled with growing awareness and improved diagnosis, is significantly boosting the market for dysmenorrhea treatment. As more women seek medical attention for menstrual pain, the demand for effective therapeutic solutions ranging from over-the-counter pain relievers to hormonal treatments continues to rise. Additionally, increased awareness campaigns and education efforts are helping to destigmatize the condition, encouraging early intervention. At the same time, key market players are accelerating product development and launching innovative treatment options, such as extended-release formulations and targeted hormonal therapies, further expanding the treatment landscape. Together, these factors are driving growth by broadening the patient base, enhancing treatment accessibility, and encouraging continuous innovation in dysmenorrhea management during the forecast period from 2025 to 2032.

Dysmenorrhea Treatment Market Dynamics:

According to the data provided by the Women Concern Health Factsheet (2024), around 80% of women experienced period pain at some stage in their lifetime. But in 5% to 10% of women, the pain is severe enough to disrupt their life. Additionally, 40% of women, period pain is accompanied by premenstrual symptoms, such as bloating, tender breasts, swollen stomach, lack of concentration, mood swings, clumsiness, and tiredness.

These painful conditions, often characterized by cramping, lower abdominal discomfort, back pain, and mood changes, can significantly impair daily activities, productivity, and overall quality of life. As a result, a growing number of women are seeking medical attention and effective relief solutions. The availability of a wide range of treatment options including nonsteroidal anti-inflammatory drugs (NSAIDs), hormonal contraceptives, dietary supplements, electrical nerve stimulation devices, and alternative therapies caters to diverse patient preferences and clinical needs thereby escalating the overall market of dysmenorrhea treatment.

Additionally, secondary dysmenorrhea which is associated with underlying gynecological disorders such as endometriosis, adenomyosis, pelvic inflammatory disease (PID), and uterine fibroids related pain further boosts the overall market of dysmenorrhea market. According to the data provided by the World Health Organization (2023), endometriosis affected roughly 10% (190 million) of reproductive-age women and girls globally. Unlike primary dysmenorrhea, which is generally managed with standard pain relief options, secondary dysmenorrhea typically requires diagnostic evaluation, specialized treatment, and long-term care, thereby leading to increased demand for advanced and targeted medical interventions.

Moreover, the World Health Organization (WHO) and UN Women have increasingly highlighted menstrual health as a key public health and gender equity issue. Their support for menstrual health education programs is encouraging women to seek diagnosis and treatment for dysmenorrhea rather than ignoring it as a normal part of menstruation.

Furthermore, the increase in product development activities among the key market players is further boosting the overall market of the dysmenorrhea treatment market. For instance, in May 2025, Matri, a fast-growing startup in the menstrual wellness space, launched Matri Pro, India's slimmest and most advanced period pain relief device. Matri Pro is designed to provide drug-free, non-invasive menstrual pain relief using a combination of advanced TENS technology.

However, the side effects of pharmacological treatments and stringent regulatory requirements for product approvals, among others are some of the key constraints that may limit the growth of the dysmenorrhea treatment market.

Dysmenorrhea Treatment Market Segment Analysis:

Dysmenorrhea Treatment Market by Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), Treatment (Drugs, Devices, and Others), End-User (Hospitals, Gynecology & Wellness Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the treatment segment of the dysmenorrhea treatment market, the devices category is estimated to account for the largest market share in 2024. The devices category is playing an increasingly pivotal role in boosting the overall dysmenorrhea treatment market, primarily due to its ability to offer non-pharmacological, safe, and user-friendly solutions for menstrual pain relief.

Devices such as Transcutaneous Electrical Nerve Stimulation (TENS) units, wearable neuromodulators, and thermal therapy products (including heat patches and warming belts) have gained substantial traction as alternatives to traditional drug therapies. These devices offer significant advantages, including minimal to no side effects, ease of use, reusability, and portability making them particularly attractive to younger populations and individuals seeking drug-free options. In a healthcare environment that is progressively embracing patient-centered care, these innovations provide women with greater autonomy and comfort in managing their menstrual symptoms.

The convenience of at-home use and rapid onset of pain relief also add to the appeal, particularly for those with busy lifestyles or who are wary of long-term medication use. Additionally, advancements in wearable technology, smartphone integration, and ergonomic designs have further improved user experience and compliance. Additionally, the development of multifunctional devices like MIMA 2.0 showcases the integration of technology in menstrual health management. MIMA 2.0 is a compact, portable, and IoT-integrated menstrual aid that combines features such as leak-proof design, antibacterial and anti-odor properties, and a Bluetooth-controlled heating system for cramp relief. This holistic approach caters to multiple menstrual discomforts, reflecting the evolving preferences of consumers for comprehensive and tech-enabled solutions.

Thus, the factors mentioned above are expected to boost the market of the segment thereby boosting the overall market of dysmenorrhea treatment during the forecast period from 2025 to 2032.

North America is expected to dominate the overall dysmenorrhea treatment market:

North America is projected to hold the largest share of the dysmenorrhea treatment market in 2024, driven by several key factors. The market is driven due to its strong healthcare infrastructure, high awareness of menstrual health, and increasing adoption of advanced medical devices. The country has witnessed a surge in demand for non-invasive and drug-free treatment options like TENS units, heat therapy devices, and wearable pain relief solutions. Additionally, a rising focus on women's health, a supportive regulatory environment, and growing investments in R&D for innovative menstrual pain relief products are contributing to market expansion.

According to the U.S. Frequency of Menstrual Pain Survey (2023), in 2023, a significant portion of women in the US reported experiencing menstrual pain, with 84% rating their cramps as moderate to severe. Menstrual pain, or dysmenorrhea, is one of the most common gynecological conditions affecting a large percentage of women of reproductive age worldwide, and its high prevalence is significantly boosting the overall market for dysmenorrhea treatment. Thus, the market is witnessing a surge in product innovation, with pharmaceutical companies developing novel NSAIDs, hormonal therapies, and extended-release contraceptives, while Femtech and MedTech companies are introducing wearable pain-relief devices, such as TENS units and heat patches, to meet the growing demand for non-pharmacological interventions.

Additionally, according to the Society of Women's Health Research (2024), fibroids are one of the most common gynecologic conditions, affecting an estimated 26 million women, ages 15 to 50, in the United States. Uterine fibroids, also known as leiomyomas, are a major underlying cause of secondary dysmenorrhea and are significantly boosting the overall market for dysmenorrhea treatment. Hormonal therapies such as GnRH antagonists, progestin-releasing intrauterine systems, and combination oral contraceptives are frequently prescribed to manage the symptoms associated with fibroids, including menstrual pain.

Additionally, the presence of key market players such as iPulse Medical manufacturer of Livia, an FDA-approved wearable device that uses TENS (Transcutaneous Electrical Nerve Stimulation) technology to provide instant relief from menstrual cramps highlight how technological innovation and consumer preference for non-pharmacological, convenient solutions are fueling the dysmenorrhea treatment market in the U.S.

Thus, the above-mentioned factors are expected to boost the dysmenorrhea treatment market in North America during the forecasted period from 2025 to 2032.

Dysmenorrhea Treatment Market Key Players:

Some of the key market players operating in the dysmenorrhea treatment market include Johnson & Johnson Services Inc., iPulse Medical Ltd., Bridges CHC, LLC., AbbVie Inc., Myoovi Ltd., Rael Inc., Abbott, Pfizer Inc., TensCare Ltd. (UK), Beurer GmbH (Germany), BPL Medical Technologies, Cora, Carex Health Brands (USA), Sumitovant Biopharma, Emcure Pharmaceuticals, Everteen, Samphire Neuroscience, Mirapulse, Welme, Nomisk, and others.

Recent Developmental Activities in the Dysmenorrhea Treatment Market:

• In September 2024, Organon K.K., a global healthcare company focused on women's health, announced that it had achieved the primary endpoint in a domestic Phase III clinical trial evaluating the efficacy and safety of OG-8276A for dysmenorrhea. Based on the trial results, the company prepared to apply for marketing approval and launch in Japan.
• In October 2023, Fuji Pharma Co., Ltd. and M3, Inc. announced that Fuji had applied for marketing approval of the estetrol/drospirenone combination product (Development code: FSN-013), co-developed in Japan, to the Ministry of Health, Labour and Welfare (MHLW) for the scheduled indication of dysmenorrhea.

Key takeaways from the dysmenorrhea treatment market report study

• Market size analysis for current dysmenorrhea treatment market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the dysmenorrhea treatment market.
• Various opportunities available for the other competitors in the dysmenorrhea treatment market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current dysmenorrhea treatment market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for dysmenorrhea treatment market growth in the coming future?

Target audience who can benefit from this dysmenorrhea treatment market report study

• Dysmenorrhea treatment product providers
• Research organizations and consulting companies
• Dysmenorrhea treatment-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in dysmenorrhea treatment
• Various end-users who want to know more about the dysmenorrhea treatment market and the latest technological developments in the dysmenorrhea treatment market.

Frequently Asked Questions for the Dysmenorrhea Treatment Market:

1. What are dysmenorrhea treatment?

• Dysmenorrhea refers to painful menstrual cramps that occur before or during menstruation. It is commonly divided into two types: primary dysmenorrhea, which involves cramping pain without any underlying medical condition, often beginning in adolescence; and secondary dysmenorrhea, which results from reproductive health issues such as endometriosis, uterine fibroids, or pelvic inflammatory disease. The condition can range from mild discomfort to severe pain that interferes with daily activities.

2. What is the market for dysmenorrhea treatment?

• The dysmenorrhea treatment market was valued at USD 4,693.08 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 7,909.14 million by 2032.

3. What are the drivers for the dysmenorrhea treatment market?

• The high prevalence of dysmenorrhea (menstrual pain), coupled with growing awareness and improved diagnosis, is significantly boosting the market for dysmenorrhea treatment. As more women seek medical attention for menstrual pain, the demand for effective therapeutic solutions ranging from over-the-counter pain relievers to hormonal treatments continues to rise. Additionally, increased awareness campaigns and education efforts are helping to destigmatize the condition, encouraging early intervention. At the same time, key market players are accelerating product development and launching innovative treatment options, such as extended-release formulations and targeted hormonal therapies, further expanding the treatment landscape. Together, these factors are driving growth by broadening the patient base, enhancing treatment accessibility, and encouraging continuous innovation in dysmenorrhea management during the forecast period from 2025 to 2032.

4. Who are the key players operating in the dysmenorrhea treatment market?

• Some of the key market players operating in the dysmenorrhea treatment market include Johnson & Johnson Services Inc., iPulse Medical Ltd., Bridges CHC, LLC., AbbVie Inc., Myoovi Ltd., Rael Inc., Abbott, Pfizer Inc., TensCare Ltd. (UK), Beurer GmbH (Germany), BPL Medical Technologies, Cora, Carex Health Brands (USA), Sumitovant Biopharma, Emcure Pharmaceuticals, Everteen, Samphire Neuroscience, Mirapulse, Welme, Nomisk, and others.

5. Which region has the highest share in the dysmenorrhea treatment market?

• North America is projected to hold the largest share of the dysmenorrhea treatment market in 2024, driven by several key factors. The market is driven due to its strong healthcare infrastructure, high awareness of menstrual health, and increasing adoption of advanced medical devices. The country has witnessed a surge in demand for non-invasive and drug-free treatment options like TENS units, heat therapy devices, and wearable pain relief solutions. Additionally, a rising focus on women's health, supportive regulatory environment, and growing investments in R&D for innovative menstrual pain relief products are contributing to market expansion.

Table of Contents

1. Dysmenorrhea Treatment Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Dysmenorrhea Treatment Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Dysmenorrhea Treatment Market Key Factors Analysis

• 5.1. Dysmenorrhea Treatment Market Drivers
  • 5.1.1. High prevalence of dysmenorrhea (menstrual pain)
  • 5.1.2. Increased awareness and diagnosis
  • 5.1.3. Increasing product development activities among the key players
• 5.2. Dysmenorrhea Treatment Market Restraints and Challenges
  • 5.2.1. Side effects of pharmacological treatments
  • 5.2.2. Stringent regulatory requirements for product approvals
• 5.3. Dysmenorrhea Treatment Market Opportunity
  • 5.3.1. Increasing demand for natural and non-hormonal alternatives

6. Dysmenorrhea Treatment Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Dysmenorrhea Treatment Market Assessment

• 7.1. By Type
  • 7.1.1. Primary Dysmenorrhea
  • 7.1.2. Secondary Dysmenorrhea
• 7.2. By Treatment
  • 7.2.1. Devices
  • 7.2.2. Drugs
  • 7.2.3. Others
• 7.3. By End-User
  • 7.3.1. Hospitals
  • 7.3.2. Gynecology & Wellness Clinics
  • 7.3.3. Homecare Settings
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.1.2. Canada Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.1.3. Mexico Dysmenorrhea Treatment Market Size in USD million (2022-2032)
  • 7.4.2. Europe
    • 7.4.2.1. France Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.2.2. Germany Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.2.3. United Kingdom Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.2.4. Italy Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.2.5. Spain Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.2.6. Rest of Europe Dysmenorrhea Treatment Market Size in USD million (2022-2032)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.3.2. Japan Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.3.3. India Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.3.4. Australia Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.3.5. South Korea Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.3.6. Rest of Asia-Pacific Dysmenorrhea Treatment Market Size in USD million (2022-2032)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.4.2. Africa Dysmenorrhea Treatment Market Size in USD million (2022-2032)
    • 7.4.4.3. South America Dysmenorrhea Treatment Market Size In USD Million (2022-2032)

8. Dysmenorrhea Treatment Market Company and Product Profiles

• 8.1. Johnson & Johnson Services Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. iPulse Medical Ltd.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. ABridges CHC, LLC.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. AbbVie Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Myoovi Ltd.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Abbott
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Pfizer Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. TensCare Ltd. (UK)
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Beurer GmbH (Germany)
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. BPL Medical Technologies
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Cora
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Carex Health Brands (USA)
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Sumitovant Biopharma
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Emcure Pharmaceuticals
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Everteen
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Samphire Neuroscience
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Mirapulse
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Welme
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Nomisk
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Rael Inc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us